Senate Introduces ONSHORE Manufacturing Act to Boost Domestic Medical Production

The Senate is taking significant steps to modernize and strengthen America's medical manufacturing capabilities with the introduction of the ONSHORE Manufacturing Act (S. 4994), spearheaded by Senator Marsha Blackburn. This pivotal legislation is designed to mitigate the United States' heavy reliance on foreign countries, especially China, for vital medical supplies and pharmaceuticals, which poses a considerable national security risk. Senator Blackburn has expressed deep concerns regarding this dependence, stating, America’s dependence on China and other foreign nations for critical medical supplies is a national security threat that puts the lives of Americans at risk.
The ONSHORE Manufacturing Act proposes a series of tax credits, to be overseen by the Internal Revenue Service (IRS), which aim to stimulate domestic production and modernization of facilities involved in the manufacturing of crucial medical supplies, drugs, and active pharmaceutical ingredients (APIs). Specifically, the act includes three vital credits: a 10.5% Domestic Manufacturing Production Credit, a 30% Advanced Manufacturing Equipment Credit, and a 30% Facility Modernization Credit. These incentives are intended to encourage manufacturers to enhance their production capabilities and ensure they meet federal standards while expanding the domestic production curve within the pharmaceuticals sector.
Enforcing compliance with the Buy American Act, the legislation wants to safeguard against future shortages that might jeopardize patient health, particularly during crises. To maintain accountability and gauge the success of these incentives, the bill mandates annual reports from relevant agencies, including the Department of Veterans Affairs, Department of Defense, and Food and Drug Administration. These reports will evaluate how effectively the act boosts domestic manufacturing capacity and adherence to procurement regulations. The potential impact of the ONSHORE Manufacturing Act extends beyond just facilitating tax credits; it signifies a paradigm shift in procurement strategies across federal agencies. Stakeholders in procurement need to be especially vigilant as agencies may modify contract requirements and supplier qualifications to prioritize domestic production. Anticipation of increased federal emphasis on sourcing domestic medical and pharmaceutical products could reshape competitive dynamics in government contracting.
For contractors working in pharmaceutical manufacturing, medical device production, and ancillary sectors, the ONSHORE Act opens up new avenues for growth and investment. The tax incentives embedded within the legislation could compel contractors to leverage these benefits for upgrading capabilities or expanding their facilities, fostering a more robust supply chain. This legislative move comes at a time when the stability of the U.S. supply chain has come under rigorous scrutiny due to ongoing global challenges, making this act timely and relevant for today’s procurement landscape. Furthermore, the endorsement of the ONSHORE Act by prominent companies such as DeRoyal Industries, Premier Inc., and Retractable Technologies underscores its significance to the industry.
By committing to bolster domestic production through strategic financial incentives, the ONSHORE Manufacturing Act is expected to create a ripple effect across various sectors reliant on medical supplies. Procurement professionals should be proactive in adjusting their strategies to align with the new framework that prioritizes domestic sourcing. As federal agencies revise their procurement policies to incorporate this act's stipulations, stakeholders in the contracting ecosystem should prepare to navigate the upcoming changes in the supply chain landscape, ensuring they remain competitive and compliant in this evolving landscape.